A Dalal - Publications, H-index & Citations

A Dalal

Pondicherry Institute of Medical Sciences

4H指数

34论文数

129被引数

收录论文 16

发表时间

A fuzzy rank-based deep ensemble methodology for multi-class skin cancer classification

SCIENTIFIC REPORTS

IF3.9

2025-02-20

OAAI

Halder, Arindam; Dalal, Anogh; Gharami, Sanghita; Wozniak, Marcin; Ijaz, Muhammad Fazal; Singh, Pawan Kumar

Prevalence and characteristics of dermatological manifestations in COVID-19 positive dermatologists: Report from a web-based survey in India

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

IF8

2021-08-17

OAAI

Jakhar, D.; Das, A.; Kaul, S.; Kaur, I.; Madke, B.; Dalal, A.

Beyond 'cure' and 'treatment success': quality of life of patients with multidrug-resistant tuberculosis

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

IF3.1

2019-01-01

PREAI

Laxmeshwar, C.; Stewart, A. G.; Dalal, A.; Kumar, A. M. V.; Kalaiselvi, S.; Das, M.; Gawde, N.; Thi, S. S.; Isaakidis, P.

BUDGET IMPACT ANALYSIS OF DABRAFENIB AND TRAMETINIB COMBINATION THERAPY IN THE TREATMENT OF BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER IN THE UNITED STATES

VALUE IN HEALTH

IF6

2017-10-01

OAAI

Zhou, Z.; Bensimon, A.; Cheng, J.; Dalal, A.

BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE

VALUE IN HEALTH

IF6

2017-10-01

OAAI

Mistry, R.; Suri, G.; Young, K. C.; Hettle, R.; May, J. R.; Brixner, D.; Oderda, G.; Biskupiak, J.; Tang, D.; Bhattacharyya, D.; Bhattacharyya, S.; Mishra, D.; Dalal, A.

COST CONSEQUENCE ANALYSIS OF DIFFERENT GENE MUTATION TESTING MODALITIES FOR BRAF V600E MUTATION IN ADVANCED NON-SMALL CELL LUNG CANCER USING A DECISION ANALYTIC MODEL

VALUE IN HEALTH

IF6

2017-10-01

OAAI

Dalal, A.; Zhou, Z.; Tang, W.; Ricculli, M. L.; Guerin, A.; Sasane, M.; Wu, K.; Culver, K.; G, Otterson; Pennell, N.

COST EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE

VALUE IN HEALTH

IF6

2017-10-01

OAAI

Suri, G.; Mistry, R.; Young, K. C.; Hettle, R.; May, J. R.; Brixner, D.; Oderda, G.; Biskupiak, J.; Tang, D.; Bhattacharyya, D.; Bhattacharyya, S.; Mishra, D.; Dalal, A.

BUDGET IMPACT ANA LYSIS OF FIRST-LINE CERITINIB IN THE TREATMENT OF ALK plus METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UNITED STATES

VALUE IN HEALTH

IF6

2017-10-01

OAAI

Mutebi, A.; Zhou, Z.; Ricculli, M. L.; Han, S.; Xie, J.; Dalal, A.; Culver, K.

PATIENT-CENTERED OUTCOMES ASSOCIATED WITH INITIAL MAINTENANCE THERAPY USE BEHAVIOR AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS WITH EMPLOYER SPONSORED INSURANCE

VALUE IN HEALTH

IF6

2016-05-01

OAAI

Patel, J.; Dalal, A.; Stanford, R.; Aparasu, R.; Abughosh, S.; Johnson, M. L.